Loading clinical trials...
Loading clinical trials...
A Phase 2 Study to Evaluate the Efficacy and Safety of an Adjuvant Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With HER2 Low Breast Cancer (Cornerstone-001)
Conditions
Interventions
AST-301(pNGVL3-hICD)
rhuGM-CSF
+3 more
Locations
17
United States
Ironwood Cancer and Research Centers
Chandler, Arizona, United States
Scripps Health
La Jolla, California, United States
Moffitt Cancer Center
Tampa, Florida, United States
University of Illinois Cancer Center
Chicago, Illinois, United States
Nebraska Cancer Specialist
Omaha, Nebraska, United States
Gabrail Cancer Center Research
Canton, Ohio, United States
Start Date
February 28, 2022
Primary Completion Date
May 31, 2024
Completion Date
May 31, 2024
Last Updated
June 17, 2024
NCT07040891
NCT07547774
NCT06257264
NCT04740697
NCT07347600
NCT05491226
Lead Sponsor
Aston Sci. Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions